JP2017537927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537927A5 JP2017537927A5 JP2017529805A JP2017529805A JP2017537927A5 JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5 JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- synergistic
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087489P | 2014-12-04 | 2014-12-04 | |
| US62/087,489 | 2014-12-04 | ||
| PCT/US2015/063585 WO2016090070A1 (en) | 2014-12-04 | 2015-12-03 | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537927A JP2017537927A (ja) | 2017-12-21 |
| JP2017537927A5 true JP2017537927A5 (enExample) | 2019-01-17 |
Family
ID=55022696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529805A Withdrawn JP2017537927A (ja) | 2014-12-04 | 2015-12-03 | がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170355768A1 (enExample) |
| EP (1) | EP3227335A1 (enExample) |
| JP (1) | JP2017537927A (enExample) |
| KR (1) | KR20170088984A (enExample) |
| CN (1) | CN107249632A (enExample) |
| AU (1) | AU2015358462A1 (enExample) |
| BR (1) | BR112017011538A2 (enExample) |
| CA (1) | CA2969665A1 (enExample) |
| EA (1) | EA201791049A1 (enExample) |
| IL (1) | IL252535A0 (enExample) |
| MX (1) | MX2017007097A (enExample) |
| SG (1) | SG11201704343SA (enExample) |
| WO (1) | WO2016090070A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2651918T3 (pl) | 2010-12-17 | 2017-12-29 | Novartis Ag | Krystaliczne formy 5-chloro-N2-(2-izopropoksy-5-metylo-4-piperydyn-4-ylofenylo)-N4-[2-(propano-2-sulfonylo)-fenylo]-pirymidyno-2,4-diaminy |
| KR102037432B1 (ko) | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CN110114089A (zh) * | 2016-11-02 | 2019-08-09 | 埃派斯进有限公司 | 组合中的抗cd40抗体及其使用方法 |
| US20210155691A1 (en) * | 2018-04-16 | 2021-05-27 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
| KR20240013793A (ko) * | 2021-05-27 | 2024-01-30 | 셀진 코포레이션 | 조합 요법을 사용하는 다발성 골수종의 치료 방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EE04852B1 (et) | 1999-02-22 | 2007-06-15 | Gesellschaft Fuer Biotechnologische Forschung Mbh | C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2008019379A2 (en) | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| AU2007281682B2 (en) | 2006-08-07 | 2013-05-16 | Abbvie Biotherapeutics Inc. | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| AU2007281684C1 (en) * | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012507555A (ja) * | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗ｃｓ１抗体の使用 |
| EP2493486A1 (en) | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| WO2011053321A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
-
2015
- 2015-12-03 AU AU2015358462A patent/AU2015358462A1/en not_active Abandoned
- 2015-12-03 KR KR1020177017909A patent/KR20170088984A/ko not_active Withdrawn
- 2015-12-03 MX MX2017007097A patent/MX2017007097A/es unknown
- 2015-12-03 CN CN201580065674.2A patent/CN107249632A/zh active Pending
- 2015-12-03 BR BR112017011538A patent/BR112017011538A2/pt not_active IP Right Cessation
- 2015-12-03 EP EP15816310.5A patent/EP3227335A1/en not_active Withdrawn
- 2015-12-03 EA EA201791049A patent/EA201791049A1/ru unknown
- 2015-12-03 JP JP2017529805A patent/JP2017537927A/ja not_active Withdrawn
- 2015-12-03 US US15/531,538 patent/US20170355768A1/en not_active Abandoned
- 2015-12-03 WO PCT/US2015/063585 patent/WO2016090070A1/en not_active Ceased
- 2015-12-03 SG SG11201704343SA patent/SG11201704343SA/en unknown
- 2015-12-03 CA CA2969665A patent/CA2969665A1/en not_active Abandoned
-
2017
- 2017-05-25 IL IL252535A patent/IL252535A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506403A5 (enExample) | ||
| JP2019526595A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| JP2015532292A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2009518441A5 (enExample) | ||
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| RU2016151757A (ru) | Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака | |
| JP2018503610A5 (enExample) | ||
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| JP2012193216A5 (enExample) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma | |
| MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
| JP2015517511A5 (enExample) | ||
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2018522028A5 (enExample) | ||
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| JP2018519300A5 (enExample) |